News About: Pharm. Industry
Huons acquires approval of ‘Elravie’ filler products in Indonesia
Huons(CEO Ki-Ahn Um), a subsidiary of Huons Global, announced ‘Elravie,’ a hyaluronic acid filler of Humedix, one of companies under the group, recently acquired Indonesian approval and would go on an expedition of ex...
Remsima turned over in market share against original medicine for first time as biosimilar
Remsima and Truxima are raising its share in the European market.
According to Celltrion Healthcare, ‘Remsima(generic name: infliximab),’ a biosimilar for the treatment of autoimmune disease, and ‘Truxima(generic nam...
Listed pharmas recording weakened cash flow from operating activities decreased by 20%
Listed pharmaceutical companies reported had a 20% decrease in cash flow from operating activities last year compared to 2015.
Yakup Shinmoon(www.yakup.com) analyzed 2017 audit reports(consolidated) 64 listed pharmac...
Hanmi Pharm, “ZAI Lab will return Chinese license of olmutinib, targeted cancer therapy”
ZAI Lab decided to return the license of ‘olmutinib(HM61713),’ a targeted therapy for cancer, due to the company’s change of new drug development strategy in Chana, and Hanmi Pharm announced on the 29th that Hanmi Pha...
Which are ‘representative’ pharmas of Korea in the current era?
While Korean pharmaceutical companies are fiercely competing each other first to become a global pharmaceutical company, people are also paying attention which will become ‘representative’ Korean pharmaceutical compan...
“We’ll become a company leading the obesity market within 10 years”
The obesity rate has finally exceeded 37% for adults over 30 in Korea, which means 1 of 3 adults are obese. Thus, Novo Nordisk, a global pharmaceutical company, has launched Saxenda(generic name: liraglutide 3.0mg), a...
Which listed pharmas spent the most in SG&A expenses?
The KOSDAQ listed pharmaceutical companies’ average SG&A(selling, general and administrative) expenses were more than 3 times higher than what KOSDAQ listed pharmaceutical companies spent. KOSDAQ listed pharmaceutical...
Listed pharmas have 57% debt ratio to capital owned in 2017
1 of 5 listed pharmaceutical companies were evaluated a company having problems in financial soundness as having more debts than their capital.
Yakup Shinmoon(www.yakup.com) analyzed 2017 audit reports that 65 KOSPI ...
Shocking appointment of early 40’s Seung-Ho Jeon as Daewoong Pharmaceutical CEO
Daewoong Pharmaceutical(CEO Seung-Ho Jeon) is following a strategy to strengthen its management with professional managers as appointing President Jae-Choon Yoon and President Seung-Ho Jeon as new Co-CEOs on the 23rd....
How Korean pharmas did with operating profits?
While KOSPI listed pharmaceutical companies’ operating profits were largely increased year-on-year last year, KOSDAQ listed pharmaceutical companies had a decrease year-on-year in the category. When it comes to the pe...
